Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 532 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust... May 29, 2026 Elucidating a Risk of Developing Second Primary Malignancy During and After... August 12, 2021 Couple Married For 48 Years Shared A Touching Moment As They... August 22, 2019 Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve... March 7, 2024 Load more HOT NEWS New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 “Supporting research is mission critical for me and always will be”... ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,...
